CRP and Alzheimer disease: To our knowledge, this is the first study to use longitudinal measurements of CRP to define a chronic condition of low-grade inflammation at baseline and demonstrate that ApoE4 interacting with chronic low-grade inflammation increased the risk of AD and shortened the latency for developing AD (Figure 1 and Figure 2).